Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar pe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijä: Erwei Zeng (14958443) (author)
Muut tekijät: Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author)
Julkaistu: 2025
Aiheet:
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
Kuvaus
Yhteenveto:<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar period of cancer diagnosis, tumor size, lymph node status, tumor grade, progesterone receptor status, chemotherapy, radiotherapy, Charlson Comorbidity Index at extension, education, and income at diagnosis.</p>